88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer
Marcus Schmidt(Johannes Gutenberg University Mainz), Uğur Şahin(Johannes Gutenberg University Mainz), Daniël Langer(The Task Force for Global Health), Michael Eichbaum(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Sebastian Newrzela(BioNTech (Germany)), Stefanie Bolte(BioNTech (Germany)), Eva Godehardt(BioNTech (Germany)), Tana Omokoko(Institute of Pathology Celle), Sebastian Attig(Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz), Isabel Vogler(BioNTech (Germany)), Evelyna Derhovanessian(University of Tübingen), Henrik Lindman(Uppsala University), Andrea Cortini(BioNTech (Germany)), Steve Pascolo(University of Zurich), Andreas Schneeweiß(German Cancer Research Center), Özlem Türeci(Johannes Gutenberg University Mainz), JOCELYN GRUTZNER(BioNTech (Germany)), Tobias Sjöblom(Uppsala University)
Cited by 34
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
|Science|2006|3.2k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k